<DOC>
	<DOCNO>NCT02486497</DOCNO>
	<brief_summary>Human equilibrative nucleoside transporter 1 ( hENT1 ) membrane transporter predict marker gemcitabine chemotherapy . However , limited evidence indicator adjuvant gemcitabine chemotherapy . In study , investigator try investigate role hENT1 indicator selection adjuvant chemotherapy regimen gemcitabine 5-fluorouracil ( 5-FU ) .</brief_summary>
	<brief_title>Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based hENT1 Immunostaining</brief_title>
	<detailed_description>After surgical resection pancreatic cancer , tissue immunostained hENT1 antibody . The grade immunostaining categorize 0 ( 0 % ) , 1 ( &lt; 50 % ) , 2 ( &gt; =50 % ) . According grade , patient grade 0 1 treat 5-FU grade 2 treated gemcitabine . After study , investigator calculate overall survival recurrence free survival patient investigate role hENT1 predictive biomarker adjuvant gemcitabine chemotherapy .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients curatively resect pancreatic cancer Age 18 75 Eastern Cooperative Oncology Group performance score 0 1 Patients compliance Patients informed consent Patients refuse enroll study Patients concomitant chemoradiation therapy Previous chemotherapy Pregnant preparing pregnancy Uncontrolled infection , diabetes , hypertension , ischemic heart disease , myocardial infarction within 6 month Enrolled another clinical trial within 30 day Patients expect risk enrollment Patients without informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>hENT1</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>